Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT00892931. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
Study identification
- NCT ID
- NCT00892931
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Myrexis Inc.
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- Azixa Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Aug 31, 2011
- Last update posted
- Oct 13, 2011
2009 – 2011
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Stanford University | Stanford | California | 94305 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Lahey Clinic | Burlington | Massachusetts | 01805 | — |
| University of Massachusettes | Worcester | Massachusetts | 01655 | — |
| Darthmouth -Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Columbia University | New York | New York | 10032 | — |
| SCCA/University of Washington | Seattle | Washington | 981209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00892931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2011 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00892931 live on ClinicalTrials.gov.